Pseudomyxoma PeritoneiNCT01427101
Results of CRS and Debulking in PMP Patients
An observational study of Pseudomyxoma Peritonei, run by Uppsala University.
Trial summary
The aim of this study was to compare debulking surgery and cytoreductive surgery in patients with Pseudomyxoma Peritonei with respect to efficacy and safety. Read more about this study
- Who is it for?
- Ages 20 to 80 years
- Conditions the study is for
- Pseudomyxoma Peritonei
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Sep 1993to not given
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with Pseudomyxoma Peritonei, sceduled for surgical treatment at Uppsala University Hospital.
Who may be able to join
- Patients with radiology histopathology finding of Pseudomyxoma Peritonei
Who cannot join
- Preformance status WHO >2 and histopathology shows other origin then Pseudomyxoma Peritonei
About this study
Official title: Comparison Between Cyotreductive Surgery and Debulking Surgery in Patients With Pseudomyxoma Peritonei
The aim of this study was to compare debulking surgery and cytoreductive surgery in patients with Pseudomyxoma Peritonei with respect to efficacy and safety.
- Conditions
- Pseudomyxoma Peritonei
- Keywords
- Pseudomyxoma Peritonei, Cytoreductive surgery, Debulking surgery, Intraperitoneal chemotherapy
- Medical subject headings
- Pseudomyxoma Peritonei
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
from treatment and forward
Secondary outcomes (1)
morbidity and mortality
mortality is messured during the first 90 postoperative days and morbidity during hospital stay.
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2011 (estimated)
- Study startSep 1993
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pseudomyxoma PeritoneiStudies of the same condition, open and under way.
- More trials run by Uppsala UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Sponsor and investigators
- Lead sponsor
- Uppsala University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Haile Mahteme, MD, PhD, Principal investigator, Uppsala University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01427101
- Sponsor's protocol ID
- 2007/073-PMP-Andréasson
- Status last verified
- Aug 2011
- First submitted
- 31 Aug 2011
- Last updated
- 1 Sep 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison Between Cyotreductive Surgery and Debulking Surgery in Patients With Pseudomyxoma Peritonei
- ClinicalTrials.gov ID
- NCT01427101
- Acronym / sponsor ID
- 2007/073-PMP-Andréasson
- Conditions
- Pseudomyxoma Peritonei
- Keywords
- Pseudomyxoma Peritonei, Cytoreductive surgery, Debulking surgery, Intraperitoneal chemotherapy
- Study type
- Observational
- Recruitment status
- Unknown status
- Lead sponsor
- Uppsala UniversityUniversity, hospital or other
- Study start
- Sep 1993
- First posted
- 1 Sep 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to compare debulking surgery and cytoreductive surgery in patients with Pseudomyxoma Peritonei with respect to efficacy and safety.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with Pseudomyxoma Peritonei, sceduled for surgical treatment at Uppsala University Hospital.
Key inclusion criteria (1 listed)
- Patients with radiology histopathology finding of Pseudomyxoma Peritonei
Key exclusion criteria (1 listed)
- Preformance status WHO >2 and histopathology shows other origin then Pseudomyxoma Peritonei
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall survival
from treatment and forward
1 secondary outcome
morbidity and mortality
Time frame: 90 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2011.
Related trials for Pseudomyxoma Peritonei
RecruitingPhase 3
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery
Acquired Fibrinogen Deficiency
Not yet recruitingPhase 2
Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum
RecruitingObservational study
Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
Peritoneal Carcinomatosis, Pseudomyxoma Peritonei
RecruitingObservational study
The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry
Appendix Cancer, Pseudomyxoma Peritonei
RecruitingPhase 2
Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
Appendiceal Mucinous Neoplasm, Pseudomyxoma Peritonei
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Haile Mahteme, MD, PhD principal investigator
Uppsala University
Questions about this trial
What is this clinical trial studying?
An observational study of Pseudomyxoma Peritonei, run by Uppsala University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Sep 2011. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2011.